Mulling biopharma’s Minority Report moment
Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.
Heightened US antitrust fears rattle biopharma
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Viridian aims to prove itself in thyroid eye
Forthcoming data will see the group take on Horizon, but subcutaneous projects could pose the real threat.
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
Spotlight – still plenty of hopefuls in lung fibrosis
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
